ClinImmune Cell and Gene Therapy has filed international patents on HLA gene editing to treat autoimmune diseases. Our research is focused on altering the peptide binding groove of the HLA molecule in order to change its ability to bind specific peptides that trigger autoimmunity. We have concluded preclinical studies on DRB1 to alter the K71 residue found in DRB1*04:01 (an RA-susceptibility allele) to E71 and demonstrated that the gene edit blocks collagen sensitization without being recognized as ‘foreign’ by the immune system. Additional studies are underway to treat multiple sclerosis, ankylosing spondylitis and Type I diabetes.
What We Do
Accreditations CertificatesView All
We have provided FDA-Approved stem-cell therapies to over 2,000 patients